Price
No data yet.
Social Signal Score
Analyst Ratings
2 analystsRevenue
$0.00Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Tao Fu
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 50
- Beta
- 0.00
- Country
- US
Financials
ATTO has only 6 quarterly periods on file — the charts below show the full history available.
Revenue
$0.00-100.0%Net Income
$-22.27MEBITDA
$-24.78MFree Cash Flow
$-25.69MEPS (diluted)
$-0.49Shares Outstanding (diluted)
293.70M+662.3%Operating Expenses
$25.02MCash & Debt
$395.94MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $1.35M | $-60.63M | $-1.42 |
| 2024 | $0.00 | $-39.80M | $-1.05 |
Valuation
ATTOhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
120+20.00%Social Signal Score
Mentions (6)
- Newsseekingalpha.com·13d ago·Positive
Attovia Therapeutics, Inc. (ATTO) Discusses ATTO-1310 Phase Ib Results in Chronic Pruritus and Atopic Dermatitis Transcript Attovia Therapeutics, Inc. (ATTO) Discusses ATTO-1310 Phase Ib Results in Chronic Pruritus and Atopic Dermatitis Transcript
View source ↗ - Newsmarketbeat.com·16d ago·Neutral
Attovia Therapeutics Reports Sustained Itch Relief in Small Study, Plans Phase 2 Trials Attovia Therapeutics NASDAQ: ATTO reported 12-week results from a small phase 1b study of its experimental itch treatment ATTO-1310, saying a single dose produced sustained responses in patients with chronic pruritus of unknown origin and in those with high-itch atopic dermatitis.
View source ↗ - Newsglobenewswire.com·55d ago·Neutral
Attovia Therapeutics to Present New Data on ATTO-1310 and ATTO-2306 at EADV 2026 and Fall Clinical Dermatology Conference 2026 SAN CARLOS, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced that it will present new clinical, translational, and preclinical data across its pipeline at the European Aca…
View source ↗ - Newsglobenewswire.com·80d ago·Neutral
Attovia Therapeutics to Participate in Upcoming Investor Conferences SAN CARLOS, Calif., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Attovia Therapeutics, Inc. (“Attovia” or the “Company”) (Nasdaq: ATTO), a clinical-stage biopharmaceutical company developing next-generation biotherapeutics for immune-mediated diseases with high unmet need, today announced that company management will participate in the following upcoming investor conferences:
View source ↗ - Newsglobenewswire.com·81d ago·Neutral
Attovia Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update ATTO-1310 demonstrated preliminary clinical proof of concept in chronic pruritus and high-itch atopic dermatitis (AD); complete Phase 1b data expected in Q4 2026
View source ↗ - News247wallst.com·97d ago·Neutral
Meet Attovia: The Clinical-Stage Biotech That Aims to Stop Chronic Itch at the Source Attovia Therapeutics (NASDAQ:ATTO) has arrived on public markets with a pipeline built entirely on one bet: that a biparatopic antibody platform called Attobody can turn well-validated immunology targets into next-generation biologics.
View source ↗
Earnings
Mon, Feb 8(in 3 months)
Consensus estimate $-0.58 per share
Typical surprise -36.7% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 9$-0.76 vs $-0.56miss
- Wed, Sep 2$-4.88 vs $-0.65miss
- Tue, Nov 15$0.10 vs $-0.17beat
- Thu, Aug 4$-0.83 vs $-0.15miss
- Thu, May 12$-0.54 vs $-0.54beat
- Thu, Mar 31$-2.43 vs $0.23miss
Estimates and results for ATTO via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by ATTO officers and directors.
- Bought
- $30.9m
- Sold
- $4.9m
18 trades
61 trades
- Walsh Colinbought
- Goldman Sachs Group Incbought
- Walsh Colinbought
- Walsh Colinbought
- Walsh Colinbought
- Walsh Colinbought
- Walsh Colinbought
- Walsh Colinsold
21 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in ATTO.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
